Bessemer Group’s Vera Therapeutics VERA Stock Holding History

Bessemer Group’s Portfolio VERA Stock Details VERA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-35	Closed	-$2K	–	2702
2024 Q3	$2K	Buy	+35	New	+$1.33K	﹤0.01%	2287

Other funds holding VERA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Bessemer Group's VERA Position: Q4 2024 in Review

Bessemer Group sold out of Vera Therapeutics (VERA) in Q4 2024, closing a stake of 35 shares — an estimated $2K sold.

Bessemer Group first reported a position in VERA in Q3 2024 and held it in 1 quarter. The position peaked at $2K in Q3 2024. 178 funds tracked by Wall St. Rank hold VERA as of Q4 2024.

Bessemer Group reported no remaining Vera Therapeutics position as of Q4 2024 after selling out during the quarter.
Bessemer Group sold 35 Vera Therapeutics shares in Q4 2024, an estimated $2K.
Bessemer Group first reported a position in Vera Therapeutics in Q3 2024 and held it in 1 quarter.
Bessemer Group's Vera Therapeutics position peaked at $2K in Q3 2024.
178 funds tracked by Wall St. Rank held Vera Therapeutics as of Q4 2024.

Based on Bessemer Group's 13F filing for Q4 2024, filed 13 Feb 2025.